AustralianSuper Pty Ltd Trims Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

AustralianSuper Pty Ltd reduced its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 39.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,961,507 shares of the company’s stock after selling 3,190,236 shares during the period. AustralianSuper Pty Ltd owned 0.43% of Teva Pharmaceutical Industries worth $100,222,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vontobel Holding Ltd. lifted its holdings in Teva Pharmaceutical Industries by 5.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company’s stock worth $12,062,000 after purchasing an additional 37,455 shares in the last quarter. Phoenix Financial Ltd. raised its position in shares of Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after buying an additional 3,533,800 shares during the last quarter. Oak Harvest Investment Services purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth $1,010,000. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after acquiring an additional 4,306,363 shares during the last quarter. Finally, Swiss National Bank grew its stake in Teva Pharmaceutical Industries by 15.5% during the second quarter. Swiss National Bank now owns 3,616,500 shares of the company’s stock valued at $60,613,000 after acquiring an additional 486,100 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Up 2.1%

TEVA opened at $33.21 on Thursday. The stock has a 50-day moving average of $30.12 and a 200 day moving average of $22.96. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $33.42. The firm has a market cap of $38.09 billion, a P/E ratio of 55.35, a P/E/G ratio of 1.85 and a beta of 0.66.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.13% and a net margin of 4.24%.The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Scotiabank started coverage on Teva Pharmaceutical Industries in a report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 target price on the stock. Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, December 22nd. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Sunday, January 18th. Finally, The Goldman Sachs Group lifted their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $33.67.

Insider Buying and Selling

In other news, Director Roberto Mignone sold 77,400 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total value of $2,340,576.00. Following the sale, the director owned 367,600 shares of the company’s stock, valued at approximately $11,116,224. This represents a 17.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the sale, the insider owned 52,828 shares of the company’s stock, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 622,060 shares of company stock valued at $17,076,965 in the last three months. Corporate insiders own 0.55% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results materially beat estimates — Teva reported $0.96 EPS vs. $0.65 consensus and revenue of $4.71B vs. $4.36B, driven by branded drug sales and milestone income; the strong print and conference‑call detail are the main catalyst lifting the stock today. Teva profit, revenue rise in fourth quarter
• Positive Sentiment: Management highlights and pipeline: company messaging and the earnings call/transcript emphasized the “pivot to growth” strategy, milestone payments and late‑stage programs (ulcerative colitis/Crohn’s), which support longer‑term upside expectations. Q4 2025 Earnings Call Transcript
• Positive Sentiment: 2025 top‑line momentum: Teva reported full‑year revenues of $17.3B (3–4% YoY growth) and called out three consecutive years of growth — supportive evidence that the business is stabilizing and shifting toward growth. GlobeNewswire: Innovative Portfolio & Pivot to Growth
• Positive Sentiment: Analyst commentary: value/growth screens and recent writeups (Zacks) are highlighting TEVA as an attractive value play given earnings beats, improving margins and pipeline progress — that helps attract buy‑side interest after the print. Zacks: Here’s Why TEVA is a Strong Value Stock
• Neutral Sentiment: Corporate PR / awareness campaign: Teva has launched a Huntington’s disease awareness partnership with Will Forte — positive for brand and patient engagement but likely limited near‑term financial impact. Will Forte Teams Up with Teva
• Negative Sentiment: FY‑2026 guidance slightly below Street expectations — Teva issued EPS guidance of $2.570–2.770 (consensus ~2.71) and revenue guidance $16.4–16.8B vs. ~$17.0B consensus; the lower revenue range is the main limiter on further upside despite the Q4 beat.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.